Veterinary Medicines

FATROXIMIN 100 mg / 13,4 g intrauterin emulzió szarvasmarhák és lovak részére A.U.V.

Authorised
  • Rifaximin
Download as PDF

Product identification

Medicine name:
FATROXIMIN 100 mg / 13,4 g intrauterin emulzió szarvasmarhák és lovak részére A.U.V.
Active substance:
  • Rifaximin
Target species:
  • Cattle
  • Horse
Route of administration:
  • Intrauterine use

Product details

Active substance and strength:
  • Rifaximin
    7.00
    milligram(s)
    /
    1.00
    gram(s)
Pharmaceutical form:
  • Intrauterine suspension
Withdrawal period by route of administration:
  • Intrauterine use
    • Cattle
      • Milk
        0
        year
      • Meat and offal
        0
        day
    • Horse
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QG51AA06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Hungary
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • Directorate Of Veterinary Medicinal Products
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Hungarian (PDF)
Published on: 27/02/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Hungarian (PDF)
Published on: 27/02/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Hungarian (PDF)
Published on: 27/02/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."